In early-stage CRC, SLC9A2 can inhibit tumor metastatic progression, while in advanced stages, it serves as an immunosensitizing molecule that reverses resistance to immunotherapy in liver metastasis. Here, SLC9A2 is linked to colorectal carcinoma.